House com­mit­tee ad­vances bills aimed at or­phan ex­clu­siv­i­ty, gener­ic la­bel­ing and con­tin­u­ous man­u­fac­tur­ing

The House En­er­gy and Com­merce Com­mit­tee on Wednes­day ad­vanced 17 health-re­lat­ed bills for con­sid­er­a­tion by the House, sev­er­al of which have im­pli­ca­tions for the FDA’s over­sight of or­phan drugs, im­port­ed med­ical de­vices and la­bel­ing.

“These bills will ex­pand cov­er­age and ac­cess to care, strength­en men­tal health par­i­ty, pro­vide men­tal health sup­port to first re­spon­ders, en­hance trans­paren­cy and op­er­abil­i­ty of the Strate­gic Na­tion­al Stock­pile and im­prove the safe­ty of Amer­i­ca’s food, drugs and med­ical de­vices,” said Com­mit­tee Chair­man Frank Pal­lone (D-NJ).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER